look news india
Lucknow, 05 July (HS). Dr. Ram Manohar Lohia Institute of Medical Sciences, Lucknow has started a new era in the field of vaccine research by starting the historic TDA-P Phase-III vaccine clinical trial.
The re-emergence of pertussis despite widespread childhood vaccination underscores the challenges posed by waning immunity over time. Traditional acellular pertussis vaccines, while safer than whole-cell precursors, often provide less durable protection.
Clinical studies have demonstrated the safety of Boostenred as well as its ability to induce higher and more persistent antibody levels compared to conventional vaccines against pertussis. The efficacy and safety of this vaccine is being tested in approximately 30 healthy adult participants who have previously received conventional DPT. The safety and immunogenicity of this vaccine will now be tested in the human community.
This research has been permitted for clinical trials after strictly following all norms of safety of the participants and is monitored by the Institutional Ethics Committee (IEC) of the institute. A group of dedicated field staff consisting of doctors and paramedical personnel will continuously monitor all the participants who have taken this vaccine for at least one month. The participants will be tested for immunity generated through blood tests, which will be done free of cost.
The trial is fully insured by ICICI Lombard and even if any of the participants face any minor side effects, it will be covered by the insurance and the entire treatment will be given free of cost to the participants.
This research is part of a multi-centric project being conducted across the country to establish the safety and efficacy of this vaccine in Indians. The entire process will be monitored by the institute's director Professor C.M. Singh.
